menu
    • menu

    Company profile for Gesynta Pharma

    NEW Drugs in Dev: 3
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Gesynta Pharma was founded on the basis of: access to potent and selective mPGES-1 inhibitors for pharmacological research and clinical development proprietary knowledge of novel aspects of biological/medical effects caused by mPGES-1 inhibition leading to new opportunities in novel indications a team with extensive experience. Gesynta Pharma has been supported by Karolinska Institutet Innovation AB, Novo Nordisk Foundation,...
    Gesynta Pharma was founded on the basis of: access to potent and selective mPGES-1 inhibitors for pharmacological research and clinical development proprietary knowledge of novel aspects of biological/medical effects caused by mPGES-1 inhibition leading to new opportunities in novel indications a team with extensive experience. Gesynta Pharma has been supported by Karolinska Institutet Innovation AB, Novo Nordisk Foundation, Swelife and VINNOVA - Swedish Governmental Agency for Innovation

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Gesynta PharmaSweden Flag
    Country
    Country
    Sweden
    Address
    Address
    Fogdevreten 2, SE-171 65 Solna
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.gesynta.se/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    BPI Europe

    BPI Europe

    Not Confirmed

    envelop Contact Supplier

    BPI Europe

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Gesynta Doses First Patient In Vipoglanstat Endometriosis Trial
    Gesynta Doses First Patient In Vipoglanstat Endometriosis Trial

    17 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/first-patient-dosed-in-gesynta-pharmas-endometriosis-trial-of-vipoglanstat-302711075.html

    PR NEWSWIRE
    17 Mar 2026
    Share Share
    Gesynta Pharma Doses First Patient in Endometriosis Trial
    Gesynta Pharma Doses First Patient in Endometriosis Trial

    11 Mar 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-03-11/first-patient-dosed-in-gesynta-pharmas-endometriosis-trial-of-vipoglanstat

    PHARMIWEB
    11 Mar 2026
    Share Share
    Gesynta Pharma receives orphan drug designation by FDA for systemic sclerosis
    Gesynta Pharma receives orphan drug designation by FDA for systemic sclerosis

    27 Apr 2022

    // PHARMAFILE

    http://www.pharmafile.com/news/626214/gesynta-pharma-receives-orphan-drug-designation-fda-systemic-sclerosis

    PHARMAFILE
    27 Apr 2022
    Share Share
    Gesynta Pharma receives orphan drug designation by FDA for systemic sclerosis
    Gesynta Pharma receives orphan drug designation by FDA for systemic sclerosis

    26 Apr 2022

    // PHARMAFILE

    http://www.pharmafile.com/news/626214/gesynta-pharma-receives-orphan-drug-designation-fda-systemic-sclerosis

    PHARMAFILE
    26 Apr 2022
    Share Share
    Gesynta Pharma announces development program for its drug candidate GS-248
    Gesynta Pharma announces development program for its drug candidate GS-248

    14 Jun 2021

    // CISION

    https://news.cision.com/let-em-know-ab/r/gesynta-pharma-announces-significant-progress-across-development-program-for-first-in-class-drug-can,c3366291#:~:text=Stockholm%2C%20Sweden%2C%20June%2014%202021,in%20patients%20with%20systemic%20sclerosis.

    CISION
    14 Jun 2021
    Share Share
    Gesynta Pharma initiates Phase II study
    Gesynta Pharma initiates Phase II study

    28 Jan 2021

    // PRESS RELEASE

    https://nordiclifescience.org/gesynta-pharma-initiates-phase-ii-study/#:~:text=Gesynta%20Pharma%20has%20announced%20that,in%20patients%20with%20systemic%20sclerosis.&text=This%20proof%2Dof%2Dconcept%20study,flow%20in%20this%20patient%20group.

    PRESS RELEASE
    28 Jan 2021
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search